Gables Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Gables Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.06K	Hold	21	–	–	﹤0.01%	424
2026 Q1	$3.97K	Hold	21	–	–	﹤0.01%	410
2025 Q4	$3.57K	Hold	21	–	–	﹤0.01%	408
2025 Q3	$2.77K	Hold	21	–	–	﹤0.01%	419
2025 Q2	$2.23K	Sell	21 -15	-42%	-$1.63K	﹤0.01%	408
2025 Q1	$4.47K	Hold	36	–	–	﹤0.01%	392
2024 Q4	$4.43K	Sell	36 -1,293	-97%	-$152K	﹤0.01%	394
2024 Q3	$148K	Sell	1,329 -830	-38%	-$91K	0.07%	142
2024 Q2	$230K	Sell	2,159 -240	-10%	-$26.4K	0.12%	109
2024 Q1	$289K	Sell	2,399 -100	-4%	-$12.2K	0.16%	103
2023 Q4	$307K	Hold	2,499	–	–	0.19%	95
2023 Q3	$323K	Sell	2,499 -82	-3%	-$10.9K	0.23%	82
2023 Q2	$320K	Sell	2,581 -65	-2%	-$8.74K	0.21%	88
2023 Q1	$387K	Hold	2,646	–	–	0.27%	76
2022 Q4	$422K	Hold	2,646	–	–	0.31%	71
2022 Q3	$353K	Sell	2,646 -135	-5%	-$20.5K	0.28%	77
2022 Q2	$434K	Sell	2,781 -65	-2%	-$10K	0.33%	71
2022 Q1	$443K	Sell	2,846 -50	-2%	-$7.26K	0.28%	82
2021 Q4	$369K	Buy	2,896 +726	+33%	+$95.4K	0.22%	93
2021 Q3	$283K	Buy	2,170 +1,643	+312%	+$248K	0.18%	104
2021 Q2	$94K	Buy	+527	New	+$91.3K	0.06%	154

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Gables Capital Management's JAZZ Position: Q2 2026 in Review

Gables Capital Management held its Jazz Pharmaceuticals (JAZZ) position steady in Q2 2026 at 21 shares worth $5.06K. The position accounts for ﹤0.01% of the portfolio, ranked #424.

Gables Capital Management first reported a position in JAZZ in Q2 2021 and has held it in 21 quarters since. The position peaked at $443K in Q1 2022. 641 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

Gables Capital Management held 21 shares of Jazz Pharmaceuticals worth $5.06K as of Q2 2026.
Gables Capital Management left its Jazz Pharmaceuticals share count unchanged in Q2 2026.
Jazz Pharmaceuticals made up ﹤0.01% of Gables Capital Management's portfolio in Q2 2026, its #424 holding.
Gables Capital Management first reported a position in Jazz Pharmaceuticals in Q2 2021 and has held it in 21 quarters since.
Gables Capital Management's Jazz Pharmaceuticals position peaked at $443K in Q1 2022.
641 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Gables Capital Management's 13F filing for Q2 2026, filed 10 Aug 2026.